Second Affiliated Hospital, School of Medicine, Zhejiang University: Lymphoma, B-Cell trials

The registry lists 15 Lymphoma, B-Cell studies with Second Affiliated Hospital, School of Medicine, Zhejiang University as lead sponsor. 10 are open to participants now and 1 have results posted.

Phase 1 10Phase 2 2No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Study of Oncolytic Vaccinia VIrus Delivering Targeted CD19 in Vivo CAR-T/M Therapy for Refractory/Relapsed B-cell LymphomaRecruitingNCT07398963Phase 1
• Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHLRecruitingNCT06707259Phase 1
• A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
• Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
• Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPIRecruitingNCT06290817Phase 2
• Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin LymphomaRecruitingNCT05667155Phase 1
• Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell LymphomaRecruitingNCT05585996Phase 1
• Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHLRecruitingNCT05472558Phase 1
• Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHLRecruitingNCT05453669Phase 1
• Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell LymphomaRecruitingNCT04887025Phase 1
• 18F-FDG PET Radiomics of Diffuse Large B-cell LymphomaCompletedNCT04317313Results posted
• Combining Intratumoral Metabolic Heterogeneity and Dissemination Feature (Dmax) on 18F-FDG PET/CT Improves Prognosis Prediction in DLBCLCompletedNCT05113576
• the Effect of Broken Ganoderma Lucidum Spore Powder on Quality of Life and Immune Function in Patients With Diffuse Large B-cell Lymphoma After ChemotherapyStatus unknownNCT04914143Not applicable
• Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHLStatus unknownNCT04887012Phase 1
• CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell LymphomaStatus unknownNCT04381741Phase 1